4991 related articles for article (PubMed ID: 12117397)
21. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study.
Crandall CJ; Hovey KM; Andrews CA; Chlebowski RT; Stefanick ML; Lane DS; Shifren J; Chen C; Kaunitz AM; Cauley JA; Manson JE
Menopause; 2018 Jan; 25(1):11-20. PubMed ID: 28816933
[TBL] [Abstract][Full Text] [Related]
22. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials.
Chlebowski RT; Rohan TE; Manson JE; Aragaki AK; Kaunitz A; Stefanick ML; Simon MS; Johnson KC; Wactawski-Wende J; O'Sullivan MJ; Adams-Campbell LL; Nassir R; Lessin LS; Prentice RL
JAMA Oncol; 2015 Jun; 1(3):296-305. PubMed ID: 26181174
[TBL] [Abstract][Full Text] [Related]
23. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
Hulley S; Furberg C; Barrett-Connor E; Cauley J; Grady D; Haskell W; Knopp R; Lowery M; Satterfield S; Schrott H; Vittinghoff E; Hunninghake D;
JAMA; 2002 Jul; 288(1):58-66. PubMed ID: 12090863
[TBL] [Abstract][Full Text] [Related]
24. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause.
Shlipak MG; Simon JA; Vittinghoff E; Lin F; Barrett-Connor E; Knopp RH; Levy RI; Hulley SB
JAMA; 2000 Apr; 283(14):1845-52. PubMed ID: 10770146
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
Grady D; Herrington D; Bittner V; Blumenthal R; Davidson M; Hlatky M; Hsia J; Hulley S; Herd A; Khan S; Newby LK; Waters D; Vittinghoff E; Wenger N;
JAMA; 2002 Jul; 288(1):49-57. PubMed ID: 12090862
[TBL] [Abstract][Full Text] [Related]
26. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.
Chlebowski RT; Anderson GL; Sarto GE; Haque R; Runowicz CD; Aragaki AK; Thomson CA; Howard BV; Wactawski-Wende J; Chen C; Rohan TE; Simon MS; Reed SD; Manson JE
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26668177
[TBL] [Abstract][Full Text] [Related]
27. Risks and benefits of menopausal hormone therapy in postmenopausal Chinese women.
Su IH; Chen YC; Hwang WT; Liu Z; Su TP; Chen TJ; Barnhart KT; Yang YX
Menopause; 2012 Aug; 19(8):931-41. PubMed ID: 22453198
[TBL] [Abstract][Full Text] [Related]
28. Failure of estrogen plus progestin therapy for prevention.
Fletcher SW; Colditz GA
JAMA; 2002 Jul; 288(3):366-8. PubMed ID: 12117403
[No Abstract] [Full Text] [Related]
29. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH;
JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206
[TBL] [Abstract][Full Text] [Related]
30. Estrogen plus progestin and colorectal cancer in postmenopausal women.
Chlebowski RT; Wactawski-Wende J; Ritenbaugh C; Hubbell FA; Ascensao J; Rodabough RJ; Rosenberg CA; Taylor VM; Harris R; Chen C; Adams-Campbell LL; White E;
N Engl J Med; 2004 Mar; 350(10):991-1004. PubMed ID: 14999111
[TBL] [Abstract][Full Text] [Related]
31. New-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk.
Crandall CJ; Aragaki AK; Chlebowski RT; McTiernan A; Anderson G; Hendrix SL; Cochrane BB; Kuller LH; Cauley JA
Arch Intern Med; 2009 Oct; 169(18):1684-91. PubMed ID: 19822825
[TBL] [Abstract][Full Text] [Related]
32. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
[TBL] [Abstract][Full Text] [Related]
33. Women's Health Initiative estrogen plus progestin clinical trial: a study that does not allow establishing relevant clinical risks.
Aedo S; Cavada G; Blümel JE; Chedraui P; Fica J; Barriga P; Brantes S; Irribarra C; Vallejo M; Campodónico Í
Menopause; 2015 Dec; 22(12):1317-22. PubMed ID: 25968833
[TBL] [Abstract][Full Text] [Related]
34. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial.
Shapiro S
Climacteric; 2003 Dec; 6(4):302-10; discussion 310-3. PubMed ID: 15006251
[TBL] [Abstract][Full Text] [Related]
35. The Women's Health Initiative Randomized Trials and Clinical Practice: A Review.
Manson JE; Crandall CJ; Rossouw JE; Chlebowski RT; Anderson GL; Stefanick ML; Aragaki AK; Cauley JA; Wells GL; LaCroix AZ; Thomson CA; Neuhouser ML; Van Horn L; Kooperberg C; Howard BV; Tinker LF; Wactawski-Wende J; Shumaker SA; Prentice RL
JAMA; 2024 May; 331(20):1748-1760. PubMed ID: 38691368
[TBL] [Abstract][Full Text] [Related]
36. Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke.
Prentice RL
Semin Reprod Med; 2014 Nov; 32(6):419-25. PubMed ID: 25321418
[TBL] [Abstract][Full Text] [Related]
37. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study.
Grady D; Wenger NK; Herrington D; Khan S; Furberg C; Hunninghake D; Vittinghoff E; Hulley S
Ann Intern Med; 2000 May; 132(9):689-96. PubMed ID: 10787361
[TBL] [Abstract][Full Text] [Related]
38. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials.
Manson JE; Aragaki AK; Rossouw JE; Anderson GL; Prentice RL; LaCroix AZ; Chlebowski RT; Howard BV; Thomson CA; Margolis KL; Lewis CE; Stefanick ML; Jackson RD; Johnson KC; Martin LW; Shumaker SA; Espeland MA; Wactawski-Wende J;
JAMA; 2017 Sep; 318(10):927-938. PubMed ID: 28898378
[TBL] [Abstract][Full Text] [Related]
39. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials.
Tang JY; Spaunhurst KM; Chlebowski RT; Wactawski-Wende J; Keiser E; Thomas F; Anderson ML; Zeitouni NC; Larson JC; Stefanick ML
J Natl Cancer Inst; 2011 Oct; 103(19):1469-75. PubMed ID: 21878677
[TBL] [Abstract][Full Text] [Related]
40. Postmenopausal hormone use and the risk of nephrolithiasis: results from the Women's Health Initiative hormone therapy trials.
Maalouf NM; Sato AH; Welch BJ; Howard BV; Cochrane BB; Sakhaee K; Robbins JA
Arch Intern Med; 2010 Oct; 170(18):1678-85. PubMed ID: 20937929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
